[Supplementary Announcement Overview](index=1&type=section&id=Supplementary%20Announcement%20Overview) This section provides an overview of the supplementary announcement, detailing its purpose and the context of the additional information provided [Purpose and Background of Announcement](index=1&type=section&id=Purpose%20and%20Background%20of%20Announcement) This announcement supplements detailed information regarding the share option scheme in Tian An Zhuo Jian Co., Ltd.'s 2024 annual report and 2025 interim report - This announcement serves as a supplement to Tian An Zhuo Jian Co., Ltd.'s 2024 annual report and 2025 interim report[2](index=2&type=chunk)[3](index=3&type=chunk) - The supplementary information primarily addresses the 'Note 42. Share Option Scheme' section in the 'Notes to the Consolidated Financial Statements' of the annual report and 'Note 22. Share Option Scheme' section in the 'Notes to the Condensed Consolidated Financial Statements' of the interim report[3](index=3&type=chunk) [Supplementary Details on Share Option Scheme](index=1&type=section&id=Supplementary%20Details%20on%20Share%20Option%20Scheme) This section provides specific details on the share option scheme, including authorized shares and their proportion to issued shares [Authorized and Issuable Shares under the Scheme](index=1&type=section&id=Authorized%20and%20Issuable%20Shares%20under%20the%20Scheme) As of various dates in 2024 and 2025, the number of share options authorized for grant and the total shares available for issue under the scheme remained constant at 72,400,363 shares Authorized and Issuable Shares under Share Option Scheme | Metric | Quantity (Shares) | | :--- | :--- | | Options authorized for grant as of January 1, 2024 | 72,400,363 | | Options authorized for grant as of December 31, 2024 | 72,400,363 | | Options authorized for grant as of January 1, 2025 | 72,400,363 | | Options authorized for grant as of June 30, 2025 | 72,400,363 | | Total shares available for issue under the scheme | 72,400,363 | [Proportion of Share Options to Issued Shares](index=1&type=section&id=Proportion%20of%20Share%20Options%20to%20Issued%20Shares) As of the annual and interim report dates, the total shares available for issue under the share option scheme represented approximately 6.7% of the total issued shares Proportion of Share Options to Issued Shares | Date | Total Issued Shares (Excluding Treasury Shares) | Proportion of Share Options to Issued Shares | | :--- | :--- | :--- | | Annual Report Date (March 10, 2025) | 1,084,815,457 Shares | Approximately 6.7% | | Interim Report Date (August 1, 2025) | 1,082,850,457 Shares | Approximately 6.7% | [Corporate Governance Information](index=1&type=section&id=Corporate%20Governance%20Information) This section outlines the composition of the Board of Directors as of a specific date [Composition of the Board of Directors](index=1&type=section&id=Composition%20of%20the%20Board%20of%20Directors) As of September 17, 2025, the Board of Directors consists of three executive, four non-executive, and four independent non-executive directors - As of September 17, 2025, the Board of Directors includes: * Executive Directors: Mr. Jiang Muxian, Mr. Guo Meibao, Mr. Zhou Haiying * Non-Executive Directors: Mr. Li Chenghui (Chairman), Mr. Wang Dajun, Mr. Gao Zhaoyuan, Ms. Zhang Yuanyuan * Independent Non-Executive Directors: Dr. Xia Xiaoning, Dr. Wang Yongquan, Ms. Yang Lichen, Mr. Cao Dan[5](index=5&type=chunk)

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 天安卓健有限公司 呈交日期： 2025年9月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前 ...

Group 1 - The company Tianan Health (00383) announced a share buyback plan [1] - The company will spend HKD 9,000 to repurchase 10,000 shares [1]

Group 1 - The company Tianan Health (00383.HK) announced a share buyback plan [1] - The buyback will occur on September 15, 2025, at a price of 9000 HKD for 10,000 shares [1] - The repurchase price per share is set at 0.9 HKD [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 表格類別： 股票 狀態： 新提交 公司名稱： 天安卓健有限公司 呈交日期： 2025年9月15日 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數 ...

Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on September 11, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1][2]. Company Buyback Details - Tencent Holdings (00700) repurchased 874,000 shares for a total of 550 million, with a year-to-date total of 54.758 million shares, representing 0.596% of its total share capital [2]. - Hang Seng Bank (00011) repurchased 210,000 shares for 24.882 million, with a year-to-date total of 6.12 million shares, representing 0.325% of its total share capital [2]. - Stone Four Pharmaceutical Group (02005) repurchased 6 million shares for 18.1433 million, with a year-to-date total of 22.6 million shares, representing 0.766% of its total share capital [2]. - MGM China (02282) repurchased 1 million shares for 16.2463 million, with a year-to-date total of 18.6274 million shares, representing 0.490% of its total share capital [2]. - Other notable companies include: - China Hongqiao (01378) with 100,500 shares repurchased for 2.4636 million, totaling 149 million shares, representing 1.590% of its total share capital [2]. - Weigao Group (01066) with 429,200 shares repurchased for 2.4248 million, totaling 10.4532 million shares, representing 2.315% of its total share capital [2]. - Coolpad Group (02369) with 924,000 shares repurchased for 1.2036 million, totaling 1.2519 million shares, representing 3.057% of its total share capital [2].

MEDICARE （於百慕達註冊成立之有限公司） (Incorporated in Bermuda with limited liability) (Stock Code: 383) （股份代號：383） NOTIFICATION LETTER 通知信函 12 September 2025 Dear Non-registered Shareholder(s) (Note), Tian An Medicare Limited (the "Company") — Notice of Publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication are available on the Company's websites at http://www.tiananmedicare.com.hk and http://www.irasia.com/listco/hk/tiananmedic ...

MEDICARE （於百慕達註冊成立之有限公司） (Incorporated in Bermuda with limited liability) (Stock Code: 383) （股份代號：383） NOTIFICATION LETTER 通知信函 12 September 2025 Dear Registered Shareholder(s), Tian An Medicare Limited (the "Company") — Notice of Publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication are available on the Company's websites at http://www.tiananmedicare.com.hk and http://www.irasia.com/listco/hk/tiananmedicare/ and th ...

如 本 公 司 於 二 零 二 五 年 十 月 十 日 或 之 前 尚 未 收 到 閣 下 已 適 當 地 填 妥 並 簽 署 的 回 條（或 表 示 反 對 以 電 子 方 式 於 本 公 司 網 站 收 取 公 司 通 訊 的 回 覆），及 直 至 閣 下 發 出 不 少 於 七 天 之 合 理 時 間 的 書 面 通 知（予 上 述 地 址 或 以 電 郵 方 式 發 送 至383-ecom@vistra.com 予 香 港 股 份 過 戶 登 記 處）前，則 閣 下 將 被 視 為 已 選 擇 只 透 過 本 公 司 網 站 收 取 日 後 的 公 司 通 訊 電 子 版 本 以 代 替 收 取 印 刷 本。在 此 情 況 下，每 當 本 公 司 發 出 公 司 通 訊 時，本 公 司 將 通 知 閣下公司通訊已登載於本公司的網站。該通知將以電郵發出（如 閣下已提供電郵地址） 或以郵寄方式（如 閣下尚未提供電郵地址）寄往 閣下於香港股份過戶登記處所存置的本公 司股東名冊上所示的地址。 閣 下 可 以 隨 時 以 合 理 時 間（不 少 於 七 日）書 面 通 知 予 本 司（寄 送 至 香 港 股 份 ...

（股份代號：383） （於百慕達註冊成立之有限公司） 2025 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 簡明綜合損益表 | 4 | | 簡明綜合損益及其他全面收益表 | 6 | | 簡明綜合財務狀況報表 | 7 | | 簡明綜合權益變動表 | 10 | | 簡明綜合現金流量表 | 11 | | 簡明綜合財務報表附註 | 13 | | 中期簡明綜合財務報表審閱報告 | 43 | | 中期股息 | 45 | | 管理層討論及分析 | 45 | | 董事之權益 | 62 | | 主要股東及其他人士於股份及相關股份之權益 | 64 | | 企業管治及其他資料 | 67 | | 審核委員會之審閱 | 68 | | 購回、出售或贖回上市證券 | 68 | 1 二零二五年中期報告 公司資料 董事會 執行董事 江木賢先生 郭美保先生 周海英先生 夏曉寧博士 王永權博士 楊麗琛女士 曹 丹先生 審核委員會 王永權博士 （主席） 高兆元先生 夏曉寧博士 楊麗琛女士 曹 丹先生 提名委員會 王永權博士 （主席） 江木賢先生 夏曉寧博士 楊麗琛女士 曹 丹先生 薪酬委員會 夏曉寧博士 （主席） 江木 ...